- Home
- QCRH vs NBTX Comparison
QCRH vs NBTX Comparison
Compare QCRH & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QCRH
- NBTX
- Stock Information
- Founded
- QCRH 1993
- NBTX 2003
- Country
- QCRH United States
- NBTX France
- Employees
- QCRH 1013
- NBTX N/A
- Industry
- QCRH Major Banks
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- QCRH Finance
- NBTX Health Care
- Exchange
- QCRH Nasdaq
- NBTX Nasdaq
- Market Cap
- QCRH 1.3B
- NBTX 1.3B
- IPO Year
- QCRH 1993
- NBTX 2020
- Fundamental
- Price
- QCRH $78.95
- NBTX $22.28
- Analyst Decision
- QCRH Buy
- NBTX Strong Buy
- Analyst Count
- QCRH 4
- NBTX 1
- Target Price
- QCRH $90.00
- NBTX $8.00
- AVG Volume (30 Days)
- QCRH 87.1K
- NBTX 77.4K
- Earning Date
- QCRH 10-22-2025
- NBTX 09-30-2025
- Dividend Yield
- QCRH 0.31%
- NBTX N/A
- EPS Growth
- QCRH 3.93
- NBTX N/A
- EPS
- QCRH 7.15
- NBTX N/A
- Revenue
- QCRH $336,623,000.00
- NBTX $11,930,711.00
- Revenue This Year
- QCRH N/A
- NBTX N/A
- Revenue Next Year
- QCRH $18.11
- NBTX $122.94
- P/E Ratio
- QCRH $11.00
- NBTX N/A
- Revenue Growth
- QCRH N/A
- NBTX N/A
- 52 Week Low
- QCRH $60.83
- NBTX $2.76
- 52 Week High
- QCRH $96.08
- NBTX $30.35
- Technical
- Relative Strength Index (RSI)
- QCRH 60.22
- NBTX 55.04
- Support Level
- QCRH $74.91
- NBTX $20.32
- Resistance Level
- QCRH $78.82
- NBTX $22.25
- Average True Range (ATR)
- QCRH 2.01
- NBTX 1.26
- MACD
- QCRH 0.15
- NBTX 0.05
- Stochastic Oscillator
- QCRH 82.17
- NBTX 68.51
About QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely Quad City Bank & Trust (QCBT), Cedar Rapids Bank & Trust (CRBT), Community State Bank (CSB) and Guaranty Bank (GB). It generates revenue in the form of interest.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.